Michael Aaron Kelly
Michael Aaron Kelly's purchase track record
Michael Aaron Kelly has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/27/2025 | NEO | $38K | -10.7% | +64.5% | +14.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
BOOM: Arcadia Put Option Launch Raises Concerns. Arcadia’s new put option on DMC Global has been launched, sparking warnings from analysts to avoid the stock. The move signals that investors may expect a decline in DMC Global’s share price. The stock is currently near the lower end of its 52‑week range, adding to concerns about further downside.
Transaction History
| NEO | ▲ Buy | Option Exercise | 23,077 | $0 | 6/1/2026 | View on chart |
| BOOM | ▲ Buy | Grant | 16,937 | $0 | 5/13/2026 | View on chart |
| NEO | ▲ Buy | Option Exercise | 12,254 | $0 | 6/1/2025 | View on chart |
| NEO | ▲ Buy | Open Market | 5,000 | $38K | 5/27/2025 | View on chart |
| BOOM | ▲ Buy | Grant | 17,580 | $0 | 5/14/2025 | View on chart |
| BOOM | ▲ Buy | Grant | 5,518 | $0 | 2/26/2025 | View on chart |
| NEO | ▲ Buy | Option Exercise | 11,336 | $0 | 8/10/2024 | View on chart |
| BOOM | ▲ Buy | Grant | 9,520 | $0 | 5/15/2024 | View on chart |
| BOOM | ▲ Buy | Grant | 7,086 | $0 | 5/10/2023 | View on chart |
| NEO | ▲ Buy | Grant | 15,556 | $0 | 6/10/2022 | View on chart |
| BOOM | ▲ Buy | Grant | 5,006 | $0 | 5/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
NeoGenomics Shares Drop 12% on CEO Transition News
NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.
NeoGenomics Shares Drop 12% on CEO Transition News. NeoGenomics stock fell 12% following the announcement of a CEO succession plan, despite reporting a revenue beat and a strong Q3 outlook. The market reaction highlights how leadership changes can outweigh immediate financial results. Analysts remain mixed, with StoneX raising its price target to $20 while the average target sits at $21.55.